p. 241−245
2008-0778
Vol.15/No.4
p. 246−251
2008-0778
Vol.15/No.4
p. 252−257
2008-0778
Vol.15/No.4
p. 258−262
2008-0778
Vol.15/No.4
p. 263−268
2008-0778
Vol.15/No.4
p. 269−274
2008-0778
Vol.15/No.4
p. 275−279
2008-0778
Vol.15/No.4
p. 280−285
2008-0778
Vol.15/No.4
p. 286−293
2008-0778
Vol.15/No.4
17 mm.Distribution of variables was evaluated visually with histograms. Continuous variables were defined by mean (standarddeviation) or median (25th-75th percentile) depending on distribution characteristics. Categorical variables weredefined by numbers and percentages. Continuous variables were compared between the groups with the t test orMann-Whitney U test as appropriate. Categorical variables were compared by the chi-square test and its derivativesas appropriate. A two-sided P<0.05 indicated statistical significance.Results: Both groups had similar antral follicle counts, median parity (0) and number of previous failed cycles (0).The median number of oocytes (8 vs. 7), metaphase-two oocytes (6 vs. 5.5), blastocysts (1 vs. 1), clinical pregnancyrates (CPR) (28% vs. 22%), ongoing pregnancy rates (OPR) (22% vs. 20%) and pregnancy rate per transfer (53.3%vs 53.8%) were similar between the dual trigger and hCG only groups, respectively.Conclusion: Dual trigger for oocyte maturation stimulation failed to improve the ICSI outcome.]]>
p. 294−299
2008-0778
Vol.15/No.4
9 mm and/or estradiol level less than 40 pg/ml after a week of recombinant follicle stimulating hormone (rFSH, 225-300 IU) administration. In that case, COS was stopped and each woman underwent weekly ultrasound assessment to catch a secondary follicular growth. All women showed at least one follicular growth within five to 20 days. Six women (54.5%) had spontaneous follicular growth and the other five required ovarian stimulation. At least one oocyte was retrieved from each one of seven patients (63.6%). The mean number of oocytes retrieved was 1.6 ± 1.4 and five women (45.5%) had at least one grade A embryo. Among all, two women became pregnant successfully and both gave live births (18.2%). In conclusion, STOP-START protocol may potentially be an effective, feasible, and time-saving management option for POSEIDON group 3/4 poor responders who are unresponsive to standard COS treatment with maximum dose gonadotrophins.]]>
p. 300−302
2008-0778
Vol.15/No.4
p. 303−304
2008-0778
Vol.15/No.4
p. 305−306
2008-0778
Vol.15/No.4